Cover Image
市場調查報告書

真性多血症:開發中產品分析

Polycythemia Vera - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192784
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
真性多血症:開發中產品分析 Polycythemia Vera - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 86 Pages
簡介

真性多血症(PV)是幹細胞異常的一種疾病,特徵是全身增生性(panhyperplastic)、惡性、腫瘤性骨髓疾病。主要症狀有疼痛和頭痛、暈眩、倦怠感、過度發汗等。此外也有風險隨年齡增加而增大的趨勢。主要治療藥有甲醇烷基化藥等。

本報告提供全球各國治療真性多血症(真性多血症)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

真性多血症概要

治療藥的開發

  • 真性多血症開發中產品:概要
  • 真性多血症開發中產品:比較分析

各企業開發中的真性多血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

真性多血症治療藥:開發中的產品一覽(各企業)

真性多血症開發治療藥的企業

  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • PharmaEssentia Corporation
  • Teva Pharmaceutical Industries Ltd.

真性多血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

真性多血症治療藥:暫停開發的產品

真性多血症治療藥:中止開發的產品

真性多血症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8360IDB

Summary

Global Markets Direct's, 'Polycythemia Vera - Pipeline Review, H2 2016', provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
  • The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects
  • The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polycythemia Vera Overview
  • Therapeutics Development
    • Pipeline Products for Polycythemia Vera - Overview
  • Polycythemia Vera - Therapeutics under Development by Companies
  • Polycythemia Vera - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Polycythemia Vera - Products under Development by Companies
  • Polycythemia Vera - Companies Involved in Therapeutics Development
    • ANP Technologies, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Galena Biopharma, Inc.
    • Gilead Sciences, Inc.
    • Italfarmaco S.p.A.
    • Karus Therapeutics Limited
    • miRagen Therapeutics, Inc.
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • PharmaEssentia Corporation
    • Teva Pharmaceutical Industries Ltd.
  • Polycythemia Vera - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • anagrelide hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arsenic trioxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idelalisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGN-4893 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • momelotinib dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ropeginterferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polycythemia Vera - Dormant Projects
  • Polycythemia Vera - Discontinued Products
  • Polycythemia Vera - Product Development Milestones
    • Featured News & Press Releases
      • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
      • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
      • Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
      • Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
      • Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
      • Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
      • Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
      • Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera
      • Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Polycythemia Vera, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Polycythemia Vera - Pipeline by ANP Technologies, Inc., H2 2016
  • Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Polycythemia Vera - Pipeline by Galena Biopharma, Inc., H2 2016
  • Polycythemia Vera - Pipeline by Gilead Sciences, Inc., H2 2016
  • Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H2 2016
  • Polycythemia Vera - Pipeline by Karus Therapeutics Limited, H2 2016
  • Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H2 2016
  • Polycythemia Vera - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
  • Polycythemia Vera - Pipeline by Novartis AG, H2 2016
  • Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H2 2016
  • Polycythemia Vera - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Polycythemia Vera - Dormant Projects, H2 2016
  • Polycythemia Vera - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Polycythemia Vera, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top